Description:
This Phase II is a multicenter, randomized, two-arm parallel-group, double-blind,
placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or
decitabine) in adult subjects with IPSS-R intermediate, high or very high risk
myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplant (HSCT) or
intensive chemotherapy.
Title
- Brief Title: A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
- Official Title: A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Clinical Trial IDs
- ORG STUDY ID:
CMBG453B12201
- SECONDARY ID:
2018-004479-11
- NCT ID:
NCT03946670
Conditions
- Myelodysplastic Syndromes
Interventions
Drug | Synonyms | Arms |
---|
MBG453 | | MBG453 + hypomethylating agents |
Placebo | | Placebo + hypomethylating agents |
Hypomethylating agents | | MBG453 + hypomethylating agents |
Purpose
This Phase II is a multicenter, randomized, two-arm parallel-group, double-blind,
placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or
decitabine) in adult subjects with IPSS-R intermediate, high or very high risk
myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplant (HSCT) or
intensive chemotherapy.
Trial Arms
Name | Type | Description | Interventions |
---|
MBG453 + hypomethylating agents | Experimental | Patients will take MBG453 plus hypomethylating agents | - MBG453
- Hypomethylating agents
|
Placebo + hypomethylating agents | Placebo Comparator | Patients will take placebo plus hypomethylating agents | - Placebo
- Hypomethylating agents
|
Eligibility Criteria
Inclusion Criteria:
1. Signed informed consent must be obtained prior to participation in the study.
2. Age ≥ 18 years at the date of signing the informed consent form (ICF)
3. Morphologically confirmed diagnosis of a myelodysplastic syndrome (MDS) based on 2016
WHO classification (Arber et al 2016) by investigator assessment with one of the
following Prognostic Risk Categories, based on the International Prognostic Scoring
System (IPSS-R):
- Very high
- High
- Intermediate with at least ≥ 5% bone marrow blast
4. Not eligible at the time of screening, for intensive chemotherapy according to the
investigator, based on local standard medical practice and institutional guidelines
for treatment decisions
5. Not eligible at the time of screening, for hematopoietic stem-cell transplantation
(HSCT) according to the investigator, based on local standard medical practice and
institutional guidelines for treatment decisions.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Exclusion Criteria:
1. Prior exposure to TIM-3 directed therapy at any time. Prior therapy with immune check
point inhibitors (e.g. anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2), cancer
vaccines are allowed except if the drug was administered within 4 months prior to
randomization.
2. Previous first-line treatment for higher risk MDS with chemotherapy or any other
antineoplastic agents including lenalidomide and hypomethylating agent (HMAs) such as
decitabine or azacitidine.
3. History of severe hypersensitivity reactions to any ingredient of the study treatment
(azacitidine, decitabine or MGB453) or their excipients, or to monoclonal antibodies
(mAbs).
4. Currently using or used within 14 days prior to randomization of systemic, steroid
therapy (> 10 mg/day prednisone or equivalent) or any immunosuppressive therapy.
Topical, inhaled, nasal, ophthalmic steroids are allowed. Replacement therapy,
steroids given in the context of a transfusion are allowed and not considered a form
of systemic treatment.
5. Investigational treatment for MDS received within 4 weeks prior to randomization. In
case of a checkpoint inhibitor: 4 months minimum prior to randomization interval is
necessary to allow enrollment.
6. Active autoimmune disease requiring systemic therapy (e.g.corticosteroids).
7. Live vaccine administered within 30 Days prior to randomization.
Other protocol-defined Inclusion/Exclusion may apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Complete remission (CR) rate |
Time Frame: | 7 months after last patient first visit (LPFV) |
Safety Issue: | |
Description: | Modified response criteria According to International Working Group (IWG) for Myelodysplastic syndromes (MDS) as per investigator assessment. |
Secondary Outcome Measures
Measure: | Overall Survival |
Time Frame: | Up to 4 years after LPFV |
Safety Issue: | |
Description: | Time from randomization to death due to any cause |
Measure: | Event Free Survival |
Time Frame: | Up to 4 years after LPFV |
Safety Issue: | |
Description: | Time from randomization to lack of reaching CR within the first 6 months, relapse from CR or death due to any cause, whichever occurs first |
Measure: | Leukemia-free survival |
Time Frame: | Up to 4 yrs after Last Patient First Visit (LPFV) |
Safety Issue: | |
Description: | Time from randomization to ≥ 20% blasts in bone marrow/ peripheral blood (per WHO 2016 classification)or diagnosis of extramedullary acute leukemia or death due to any cause |
Measure: | Response Rate (CR/mCR/PR/HI) |
Time Frame: | 7 months after Last Patient First Visit (LPFV) |
Safety Issue: | |
Description: | Percentage of complete remission(CR)/marrow Complete Remission (mCR)/partial remission (PR) and Hematological improvement (HI) according to IWG-MDS as per investigator assessment |
Measure: | Duration of complete remission |
Time Frame: | Up to 4 yrs after Last Patient First Visit (LPFV) |
Safety Issue: | |
Description: | Time from the date of the first documented CR to the date of first documented relapse from CR or death due to any cause, whichever occurs first |
Measure: | Time to complete remission |
Time Frame: | 7 months after Last Patient First Visit (LPFV) |
Safety Issue: | |
Description: | Time from randomization to the first documented CR |
Measure: | Percent of subjects who are red blood cells (RBC)/platelets transfusion independent after randomization as per IWG-MDS |
Time Frame: | Up to 4 years after last randomized patient |
Safety Issue: | |
Description: | Improvement in RBC/platelets transfusion independence |
Measure: | Red blood cells (RBC)/platelets transfusion independence duration after randomization |
Time Frame: | Up to 4 years after last randomized patient |
Safety Issue: | |
Description: | Duration of transfusion independence |
Measure: | Serum concentrations for MBG453 |
Time Frame: | At Day 8 of each cycle (1 cycle = 28 days) until cycle 6 and at day 8 of cycles 9, 12, 18 and 24, and up to 150 day of the safety follow up period |
Safety Issue: | |
Description: | Pharmacokinetics of MBG453 when given in combination with hypomethylating agents (HMA) |
Measure: | Immunogenicity of MBG453 when given in combination of hypomethylating agents |
Time Frame: | Up to 4 years after Last Patient First Visit (LPFV) |
Safety Issue: | |
Description: | Anti-drug Antibody (ADA) prevalence at baseline and ADA incidence on-treatment |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Novartis Pharmaceuticals |
Trial Keywords
- Sabatolimab
- Phase II
- MBG453
- TIM-3
- decitabine
- azacitidine
- myelodysplastic syndrome (MDS)
Last Updated
June 18, 2021